CXCR2 inhibition in pancreatic cancer: opportunities for immunotherapy?

Immunotherapy. 2017 Jan;9(1):9-12. doi: 10.2217/imt-2016-0115.
No abstract available

Keywords: CXCR2; anti-PD1; chemokines; immunotherapy; metastasis; pancreatic cancer.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • B7-H1 Antigen / immunology
  • Carcinoma, Ductal / immunology
  • Carcinoma, Ductal / therapy*
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Humans
  • Immunotherapy / methods*
  • Inflammation / immunology
  • Inflammation / therapy*
  • Myeloid-Derived Suppressor Cells / immunology*
  • Pancreatic Neoplasms / immunology
  • Pancreatic Neoplasms / therapy*
  • Receptors, Interleukin-8B / antagonists & inhibitors*
  • Signal Transduction

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • B7-H1 Antigen
  • Receptors, Interleukin-8B